Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.4900 per share.
- Transaction Volume: 454.329 shares.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Mr. S A Hussain, President of Global Pharmaceuticals. This change resulted from the re-investment of dividends paid on July 14, 2016, under the Company's Deferred Investment Award Programme. No material changes to the company's overall financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of an insider transaction.
Key Facts for Investor Verification
- Verify the identity of the PDMR: Mr. S A Hussain, President, Global Pharmaceuticals.
- Confirm the transaction date of July 14, 2016, and the filing date of July 18, 2016.
- Note that the transaction was an automatic dividend re-investment, not a discretionary open-market purchase.
- Understand that this filing contains no operational or financial performance data for the company.